These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
202 related articles for article (PubMed ID: 35731050)
1. Construction of a hypoxic immune microenvironment associated gene-based model for prognosis prediction of lung adenocarcinoma. Lin GY; Wu S; Gao ZS; Wu LH; Yan JJ; Guo XQ; Wang ZY Eur Rev Med Pharmacol Sci; 2022 Jun; 26(11):3807-3826. PubMed ID: 35731050 [TBL] [Abstract][Full Text] [Related]
2. Hypoxia-related gene signature for predicting LUAD patients' prognosis and immune microenvironment. Chen J; Fu Y; Hu J; He J Cytokine; 2022 Apr; 152():155820. PubMed ID: 35176657 [TBL] [Abstract][Full Text] [Related]
3. Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis. Shu J; Jiang J; Zhao G Front Immunol; 2023; 14():1177847. PubMed ID: 37583701 [TBL] [Abstract][Full Text] [Related]
4. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes. Li F; Niu Y; Zhao W; Yan C; Qi Y Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857 [TBL] [Abstract][Full Text] [Related]
5. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma. Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X Front Immunol; 2023; 14():1070953. PubMed ID: 37334367 [TBL] [Abstract][Full Text] [Related]
6. A novel ferroptosis-related genes model for prognosis prediction of lung adenocarcinoma. Li F; Ge D; Sun SL BMC Pulm Med; 2021 Jul; 21(1):229. PubMed ID: 34256754 [TBL] [Abstract][Full Text] [Related]
7. Development and Validation of a Machine Learning Prognostic Model of m5C Related immune Genes in Lung Adenocarcinoma. Cao X; Ji Y; Li J; Liu Z; Chen C Cancer Control; 2024; 31():10732748241237414. PubMed ID: 38537151 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of CCR2 as an immune indicator in lung adenocarcinoma: A study based on tumor-infiltrating immune cell analysis. Wan Y; Wang X; Liu T; Fan T; Zhang Z; Wang B; Zhang B; Tian Z; Mao T; Gong Z; Zhang L Cancer Med; 2021 Jun; 10(12):4150-4163. PubMed ID: 33949150 [TBL] [Abstract][Full Text] [Related]
9. A novel transcriptomic signature associated with lymphovascular invasion predicts clinical outcomes, tumor microenvironment, and therapeutic response in lung adenocarcinoma. Huang X; Feng Y; Li Y; Ding H; Huang X; Chen C; Yu Z; Zhang J; Xu X; Ma D; Yu S; Chen C Int Immunopharmacol; 2024 Jan; 127():111286. PubMed ID: 38064818 [TBL] [Abstract][Full Text] [Related]
10. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma. Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q Front Immunol; 2021; 12():693062. PubMed ID: 34497605 [TBL] [Abstract][Full Text] [Related]
11. Construction and validation of a hypoxia-related risk signature identified EXO1 as a prognostic biomarker based on 12 genes in lung adenocarcinoma. Chen Q; Chen S; Wang J; Zhao Y; Ye X; Fu Y; Liu Y Aging (Albany NY); 2023 Mar; 15(6):2293-2307. PubMed ID: 36971680 [TBL] [Abstract][Full Text] [Related]
12. Identification of prognostic gene signature associated with microenvironment of lung adenocarcinoma. Yue C; Ma H; Zhou Y PeerJ; 2019; 7():e8128. PubMed ID: 31803536 [TBL] [Abstract][Full Text] [Related]
13. Identification of a combined hypoxia and lactate metabolism prognostic signature in lung adenocarcinoma. Sun J; Jiang R; Hou L; Wang L; Li M; Dong H; Dong N; Lin Y; Zhu Z; Zhang G; Zhang Y BMC Pulm Med; 2024 Jul; 24(1):323. PubMed ID: 38965505 [TBL] [Abstract][Full Text] [Related]
14. Profiles of immune infiltration in lung adenocarcinoma and their clinical significant: A gene-expression-based retrospective study. Chen G; Dong Z; Wu D; Chen Y J Cell Biochem; 2020 Nov; 121(11):4431-4439. PubMed ID: 32003059 [TBL] [Abstract][Full Text] [Related]
15. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients. Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714 [TBL] [Abstract][Full Text] [Related]
16. Identification and validation of a novel prognostic model of inflammation-related gene signature of lung adenocarcinoma. Luo D; Feng W; Ma Y; Jiang Z Sci Rep; 2022 Aug; 12(1):14729. PubMed ID: 36042374 [TBL] [Abstract][Full Text] [Related]
17. Establishment of Immune-related Gene Pair Signature to Predict Lung Adenocarcinoma Prognosis. Jiang X; Gao Y; Zhang N; Yuan C; Luo Y; Sun W; Zhang J; Ren J; Gong Y; Xie C Cell Transplant; 2020; 29():963689720977131. PubMed ID: 33334139 [TBL] [Abstract][Full Text] [Related]
18. Molecular Typing Based on Oxidative Stress Genes and Establishment of Prognostic Characteristics of 7 Genes in Lung Adenocarcinoma. Tu J; Tang M; Li G; Chen L; Huang Y Oxid Med Cell Longev; 2022; 2022():9683819. PubMed ID: 36148413 [TBL] [Abstract][Full Text] [Related]
19. A Novel Prognostic Signature Revealed the Interaction of Immune Cells in Tumor Microenvironment Based on Single-Cell RNA Sequencing for Lung Adenocarcinoma. Jin X; Hu Z; Sui Q; Zhao M; Liang J; Liao Z; Zheng Y; Wang H; Shi Y J Immunol Res; 2022; 2022():6555810. PubMed ID: 35812244 [TBL] [Abstract][Full Text] [Related]
20. Characteristic of molecular subtypes in lung adenocarcinoma based on m6A RNA methylation modification and immune microenvironment. Zhou H; Zheng M; Shi M; Wang J; Huang Z; Zhang H; Zhou Y; Shi J BMC Cancer; 2021 Aug; 21(1):938. PubMed ID: 34416861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]